Overview
Background
Andrew Martin is inaugural Professor of Innovative Clinical Trials and leads the University of Queensland’s cLinical Trials cApability (ULTRA) program. Andrew was Professor in the biostatistics group at the NHMRC Clinical Trials Centre University of Sydney. He maintains that role in an honorary capacity since joining UQ. Prior to academia, Andrew held senior biostatistics roles within research-based pharmaceutical organisations (Pfizer and Roche).
Grants
Category 1: $14.3M Category 3: $131.8M
Grants: 2023 Clinical Trials and Cohort Studies Grant ID 2032441 ($1,362,000): P3BEP Trial - Accelerating First-Line Chemotherapy to Improve Cure Rates for Advanced Germ Cell Tumours; 2022 NHMRC Partnership Projects Grant 2015773 ($1,166,592): Strengthening healthcare systems with Patient Reported Outcome Measures (PROMs); 2020 CA ($600,000): Immuno-metabolic biomarkers for metastatic prostate cancer treatment response; 2018 MRFF Grant APP1170066 ($1,596,631): WHEAT Study on reducing NEC in preterm infants; 2018 CA Grant APP1158397 ($479,375): SCORE trial for shared colorectal cancer care; 2018 CA Grant APP1159837 ($600,000): P3BEP Trial for advanced germ cell tumours; 2018 NHMRC Project Grant APP1159787 ($1,587,163): BCG+MM Trial for bladder cancer; 2016 Victorian Cancer ($300,000): SCORE project on shared care of Colorectal cancer survivors; 2015 CA Priority-driven Collaborative Cancer Research Scheme ($443,307): LEAD - Lung cancer diagnostic and treatment pathways; 2015 NHMRC Project Grant 1108328 ($624,824): Oral Nicotinamide for skin cancer chemoprevention after Transplant; 2014 Co-funded Grant 1079794 ($597,095): Methoxyflurane to reduce discomfort of prostate biopsy; 2013 NHMRC Project Grant 1064121 ($880,425): CHEST Australia project for quicker primary care consultations in lung cancer; 2012 NHMRC Project Grant APP1047100 ($2,203,171): Bovine lactoferrin study on low birthweight infants; 2011 National Breast Cancer Foundation ($199,606): Physical well-being for metastatic breast cancer; 2011 NHMRC Project Grant 1028555 ($187,018): Evidence on reduced child obesity rates; 2011 NHMRC Project Grant 1026977 ($586,691): Oral nicotinamide for skin cancer prevention; 2011 Australasian College of Dermatologists grant ($25,000): Nicotinamide for non-melanoma skin cancer in renal transplant recipients; 2010 NHMRC Project Grant 1007628 ($369,208): NEU-HORIZONS study on riluzole for oxaliplatin neurotoxicity; 2010 NHMRC Project Grant 1003414 ($564,410): Phase II prostate cancer follow-up trial in primary care.
Statistical lead on the following projects receiving industry funding with USyd as administering institution: ENZARAD NCT02446444 ($12,178,000); ENZAMET NCT02446405 ($20,408,129); INTEGRATE ACTRN12612000239864 ($6,900,000); INTEGRATE IIa ACTRN12616000420448 ($22,264,248); INTEGRATE IIb NCT04879368 ($36,330,215); DASL-HiCaP NCT04136353 ($33,777,579).
Availability
- Professor Andrew Martin is:
- Available for supervision
Research impacts
Research Achievements and Collaborations: Has made original, innovative, and distinguished contributions to methodological research, as well as the design, conduct, analysis, interpretation, and dissemination of clinical research that has had an impact at an international level policy, practice, and subsequent research programs. Has been responsible for the provision of statistical leadership to collaborative trials groups to design, undertake, analyse, and report on clinical trials, as well as promoting investigator-initiated research activities. 2020-2024 Scopus/SciVal author publication metrics: FWCI of 5.21, 51% in top 10% most cited worldwide, 39% international collaboration 3,763 citations (10,934 overall). Received the 2020 ACTA (Australian Clinical Trials Alliance) Statistics in Trials Interest Group Excellence in Trial Statistics Award for ENZAMET Trial. Research funding in last 5 years: $3.1M category 1 and $76.7M category 3.
Contributions to the Field: Led methodological research with international impact. Examples in the last 5 years focus on the topic of changes to the design of ongoing trials. This work has been cited in the CONSERVE 2021 Statement (JAMA. 2021;326(3):257-265 FWCI 7.38; top 1% of general medical journals). Also co-published innovative method for appropriately adjusting estimates of effect obtained from trials that terminate early based on the results of an interim analysis (Statistical Methods in Medical Research – top 11% for statistics journals). Co-designed andled the statistical aspects of design, conduct, analysis, and interpretation of many trial. Two key examples in the last 5 years include ENZAMET and TheraP. (1) ENZAMET study selected for plenary presentation at ASCO (peak international clinical oncology conference attended by over 30,000 international delegates). Am second author for both main N Engl J Med paper (2019;381:121) (journal ranked top 1% general medicine), the quality of life J Clin Oncol paper (2022;40:837-46) (journal ranked top 2% cancer research), and the follow-up Lancet Oncol paper (2022;23:1389) (journal ranked top 1% cancer research). Results were used in support of successful registration of enzalutamide with US FDA in this indication and have been incorporated into US and European treatment guidelines. (2) TheraP evaluated efficacy of cutting-edge targeted radiopharmaceutical (Lu-PSMA) in advance prostate cancer that delivers radiation to cells expressing the prostate-specific membrane antigen. Selected for oral presentation at highly prestigious ASCO 2020 and ASCO GU 2021 conferences. Second senior author of The Lancet paper (2021;397:797) (journal ranked top 1% general medicine). Has led to 2 additional RCTs of Lu-PSMA that I co-designed. One (ENZA-p) was just published in Lancet Oncol (2024 Apr 12:S1470-2045(24)00135-9) (journal ranked top 1% cancer research).
Works
Search Professor Andrew Martin’s works on UQ eSpace
2020
Journal Article
Nicotinamide for skin cancer chemoprevention: Effects of nicotinamide on melanoma: In vitro and in vivo
Malesu, Rashi, Martin, Andrew J., Lyons, J. Guy, Scolyer, Richard A., Chen, Andrew C., McKenzie, Catriona A., Madore, Jason, Halliday, Gary M. and Damian, Diona L. (2020). Nicotinamide for skin cancer chemoprevention: Effects of nicotinamide on melanoma: In vitro and in vivo. Photochemical and Photobiological Sciences, 19 (2), 171-179. doi: 10.1039/c9pp00388f
2020
Journal Article
Lactoferrin infant feeding trial_Canada (LIFT_Canada): Protocol for a randomized trial of adding lactoferrin to feeds of very-low-birth-weight preterm infants
Asztalos, Elizabeth V., Barrington, Keith, Lodha, Abhay, Tarnow-Mordi, William and Martin, Andrew (2020). Lactoferrin infant feeding trial_Canada (LIFT_Canada): Protocol for a randomized trial of adding lactoferrin to feeds of very-low-birth-weight preterm infants. BMC Pediatrics, 20 (1) 40, 1-8. doi: 10.1186/s12887-020-1938-0
2019
Journal Article
Physical Activity for Symptom Management in Women With Metastatic Breast Cancer: A Randomized Feasibility Trial on Physical Activity and Breast Metastases
Yee, Jasmine, Davis, Glen M., Hackett, Daniel, Beith, Jane M., Wilcken, Nicholas, Currow, David, Emery, Jon, Phillips, Jane, Martin, Andrew, Hui, Rina, Harrison, Michelle, Segelov, Eva and Kilbreath, Sharon L. (2019). Physical Activity for Symptom Management in Women With Metastatic Breast Cancer: A Randomized Feasibility Trial on Physical Activity and Breast Metastases. Journal of Pain and Symptom Management, 58 (6), 929-939. doi: 10.1016/j.jpainsymman.2019.07.022
2019
Journal Article
Should Genital Hiatus/Perineal Body Be Measured at Rest or on Valsalva?
Ow, Lin Li, Subramaniam, Nishamini, Kamisan Atan, Ixora, Friedman, Talia, Martin, Andrew and Dietz, Hans Peter (2019). Should Genital Hiatus/Perineal Body Be Measured at Rest or on Valsalva?. Female Pelvic Medicine and Reconstructive Surgery, 25 (6), 415-418. doi: 10.1097/SPV.0000000000000608
2019
Journal Article
TheraP: a randomized phase 2 trial of 177Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603)
Hofman, Michael S., Emmett, Louise, Violet, John, Y. Zhang, Alison, Lawrence, Nicola J., Stockler, Martin, Francis, Roslyn J., Iravani, Amir, Williams, Scott, Azad, Arun, Martin, Andrew, McJannett, Margaret and Davis, Ian D. (2019). TheraP: a randomized phase 2 trial of 177Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603). BJU International, 124 (S1), 5-13. doi: 10.1111/bju.14876
2019
Journal Article
Accuracy and Prognostic Significance of Oncologists’ Estimates and Scenarios for Survival Time in Advanced Gastric Cancer
Vasista, Anuradha, Stockler, Martin, Martin, Andrew, Pavlakis, Nick, Sjoquist, Katrin, Goldstein, David, Gill, Sanjeev, Jain, Vikram, Liu, Geoffrey, Kannourakis, George, Kim, Yeul Hong, Nott, Louise, Snow, Stephanie, Burge, Matthew, Harris, Dean, Jonker, Derek, Chua, Yu Jo, Epstein, Richard, Bonaventura, Antony and Kiely, Belinda (2019). Accuracy and Prognostic Significance of Oncologists’ Estimates and Scenarios for Survival Time in Advanced Gastric Cancer. Oncologist, 24 (11), e1102-e1107. doi: 10.1634/theoncologist.2018-0613
2019
Journal Article
Postoperative pain and comfort scores: Do they correlate?
Miu, Michelle W., Martin, Andrew and Cyna, Allan M. (2019). Postoperative pain and comfort scores: Do they correlate?. Anaesthesia and Intensive Care, 47 (5), 435-441. doi: 10.1177/0310057X19861985
2019
Journal Article
Assumptions, damn assumptions and statistics
Simes, R. J. and Martin, A. J. (2019). Assumptions, damn assumptions and statistics. Annals of Oncology, 30 (9), 1415-1416. doi: 10.1093/annonc/mdz209
2019
Journal Article
Enzalutamide with standard first-line therapy in metastatic prostate cancer
Davis, Ian D., Martin, Andrew J., Stockler, Martin R., Begbie, Stephen, Chi, Kim N., Chowdhury, Simon, Coskinas, Xanthi, Frydenberg, Mark, Hague, Wendy E., Horvath, Lisa G., Joshua, Anthony M., Lawrence, Nicola J., Marx, Gavin, McCaffrey, John, McDermott, Ray, McJannett, Margaret, North, Scott A., Parnis, Francis, Parulekar, Wendy, Pook, David W., Neil Reaume, M., Sandhu, Shahneen K., Tan, Alvin, Hsiang Tan, T., Thomson, Alastair, Tu, Emily, Vera-Badillo, Francisco, Williams, Scott G., Yip, Sonia ... for the ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (2019). Enzalutamide with standard first-line therapy in metastatic prostate cancer. New England Journal of Medicine, 381 (2), 121-131. doi: 10.1056/NEJMoa1903835
2019
Journal Article
The Chest Australia Trial: A randomised controlled trial of an intervention to increase consultation rates in smokers at risk of lung cancer
Emery, Jon D., Murray, Sonya R., Walter, Fiona M., Martin, Andrew, Goodall, Stephen, Mazza, Danielle, Habgood, Emily, Kutzer, Yvonne, Barnes, David John and Murchie, Peter (2019). The Chest Australia Trial: A randomised controlled trial of an intervention to increase consultation rates in smokers at risk of lung cancer. Thorax, 74 (4), 362-370. doi: 10.1136/thoraxjnl-2018-212506
2019
Journal Article
Oncologists’ perceptions on the usefulness of geriatric assessment measures and the CARG toxicity score when prescribing chemotherapy for older patients with cancer
Moth, Erin B., Kiely, Belinda E., Stefanic, Natalie, Naganathan, Vasikaran, Martin, Andrew, Grimison, Peter, Stockler, Martin R., Beale, Philip and Blinman, Prunella (2019). Oncologists’ perceptions on the usefulness of geriatric assessment measures and the CARG toxicity score when prescribing chemotherapy for older patients with cancer. Journal of Geriatric Oncology, 10 (2), 210-215. doi: 10.1016/j.jgo.2018.11.004
2019
Journal Article
Predicting chemotherapy toxicity in older adults: Comparing the predictive value of the CARG Toxicity Score with oncologists’ estimates of toxicity based on clinical judgement
Moth, Erin B., Kiely, Belinda E., Stefanic, Natalie, Naganathan, Vasikaran, Martin, Andrew, Grimison, Peter, Stockler, Martin R., Beale, Philip and Blinman, Prunella (2019). Predicting chemotherapy toxicity in older adults: Comparing the predictive value of the CARG Toxicity Score with oncologists’ estimates of toxicity based on clinical judgement. Journal of Geriatric Oncology, 10 (2), 202-209. doi: 10.1016/j.jgo.2018.08.010
2019
Journal Article
Neurocognitive function and quality of life outcomes in the ONTRAC study for skin cancer chemoprevention by nicotinamide
Martin, Andrew J., Dhillon, Haryana M., Vardy, Janette L., Dalziell, Robyn A., Choy, Bonita, Fernández-Peñas, Pablo, Dixon, Ann, Renton, Corrinne, St. George, Gayathri, Chinniah, Niranthari, Halliday, Gary M., Damian, Diona L. and Chen, Andrew C. (2019). Neurocognitive function and quality of life outcomes in the ONTRAC study for skin cancer chemoprevention by nicotinamide. Geriatrics, 4 (1) 31, 1-6. doi: 10.3390/geriatrics4010031
2019
Journal Article
The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis
Lee, Kirsty Wai Chung, Lord, Sally, Finn, Richard S., Lim, Elgene, Martin, Andrew, Loi, Sherene, Lynch, Jodi, Friedlander, Michael and Lee, Chee Khoon (2019). The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis. Breast Cancer Research and Treatment, 174 (1), 271-278. doi: 10.1007/s10549-018-5054-x
2019
Journal Article
A Reduction in Inflammatory Macrophages May Contribute to Skin Cancer Chemoprevention by Nicotinamide
Minocha, Rashi, Martin, Andrew J., Chen, Andrew C., Scolyer, Richard A., Lyons, J. Guy, McKenzie, Catriona A., Madore, Jason, Halliday, Gary M. and Damian, Diona L. (2019). A Reduction in Inflammatory Macrophages May Contribute to Skin Cancer Chemoprevention by Nicotinamide. Journal of Investigative Dermatology, 139 (2), 467-469. doi: 10.1016/j.jid.2018.08.018
2019
Journal Article
Treatments used for obsessive–compulsive disorder—An international perspective
Brakoulias, Vlasios, Starcevic, Vladan, Albert, Umberto, Arumugham, Shyam Sundar, Bailey, Brenda E., Belloch, Amparo, Borda, Tania, Dell'Osso, Liliana, Elias, Jason A., Falkenstein, Martha J., Ferrao, Ygor A., Fontenelle, Leonardo F., Jelinek, Lena, Kalogeraki, Leto, Kay, Brian, Laurito, Luana D., Lochner, Christine, Maina, Giuseppe, Marazziti, Donatella, Martin, Andrew, Matsunaga, Hisato, Miguel, Euripedes C., Morgado, Pedro, Mourikis, Irakis, Pasquini, Massimo, Perez Rivera, Rodrigo, Potluri, Sriramya, Reddy, Janardhan Y.C., Riemann, Brian C. ... Fineberg, Naomi A. (2019). Treatments used for obsessive–compulsive disorder—An international perspective. Human Psychopharmacology, 34 (1) e2686, 1-10. doi: 10.1002/hup.2686
2018
Journal Article
Protocol for the Lactoferrin Infant Feeding Trial (LIFT): A randomised trial of adding lactoferrin to the feeds of very-low birthweight babies prior to hospital discharge
Martin, Andrew, Ghadge, Alpana, Manzoni, Paolo, Lui, Kei, Brown, Rebecca, Tarnow-Mordi, William, Lu, Kei, Simes, John, Hague, Wendy, Osborn, David, Deshpande, Girish, Kochar, Anu, Lewis, Tony, Watkins, Andrew, Pritchard, Margo, Schofield, Deborah, Mohamed, Abdel Latif, Soll, Roger, Darlow, Brian, Isaacs, David, Wilkinson, Dominic, Wood, Alicia, McKenzie, Anne, Despande, Girish, Verry, Hannah, Wright, Ian, Askie, Lisa, Cruz, Melinda, Berry, Nina ... Espinoza, David (2018). Protocol for the Lactoferrin Infant Feeding Trial (LIFT): A randomised trial of adding lactoferrin to the feeds of very-low birthweight babies prior to hospital discharge. BMJ Open, 8 (10) e023044. doi: 10.1136/bmjopen-2018-023044
2018
Journal Article
Effect Sizes Hypothesized and Observed in Contemporary Phase III Trials of Targeted and Immunological Therapies for Advanced Cancer
Lawrence, Nicola Jane, Roncolato, Felicia, Martin, Andrew, Simes, Robert John and Stockler, Martin R. (2018). Effect Sizes Hypothesized and Observed in Contemporary Phase III Trials of Targeted and Immunological Therapies for Advanced Cancer. JNCI Cancer Spectrum, 2 (4) pky037, 1-7. doi: 10.1093/JNCICS/PKY037
2018
Journal Article
Protocol for the P3BEP trial (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours
Lawrence, Nicola J., Chan, Howard, Toner, Guy, Stockler, Martin R., Martin, Andrew, Yip, Sonia, Wong, Nicole, Yeung, Annie, Mazhar, Danish, Pashankar, Farzana, Frazier, Lindsay, McDermott, Ray, Walker, Roderick, Tan, Hsiang, Davis, Ian D. and Grimison, Peter (2018). Protocol for the P3BEP trial (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours. BMC Cancer, 18 (1) 854, 1-6. doi: 10.1186/s12885-018-4745-3
2018
Journal Article
The LEAD study protocol: A mixed-method cohort study evaluating the lung cancer diagnostic and pre-treatment pathways of patients from Culturally and Linguistically Diverse (CALD) backgrounds compared to patients from Anglo-Australian backgrounds
Mazza, Danielle, Lin, Xiaoping, Walter, Fiona M., Young, Jane M., Barnes, David J., Mitchell, Paul, Brijnath, Bianca, Martin, Andrew and Emery, Jon D. (2018). The LEAD study protocol: A mixed-method cohort study evaluating the lung cancer diagnostic and pre-treatment pathways of patients from Culturally and Linguistically Diverse (CALD) backgrounds compared to patients from Anglo-Australian backgrounds. BMC Cancer, 18 (1) 754, 1-8. doi: 10.1186/s12885-018-4671-4
Funding
Current funding
Supervision
Availability
- Professor Andrew Martin is:
- Available for supervision
Before you email them, read our advice on how to contact a supervisor.
Supervision history
Current supervision
-
Doctor Philosophy
Advanced methods for biomarker informed endometrial cancer
Associate Advisor
Other advisors: Dr Eva Baxter, Dr Zoe West, Professor Andreas Obermair
Media
Enquiries
For media enquiries about Professor Andrew Martin's areas of expertise, story ideas and help finding experts, contact our Media team: